|Systematic (IUPAC) name|
|Molar mass||525.56 g/mol|
|(what is this?)|
It is being developed by Merck & Co.. The phase III clinical trial for this compound was stopped early after a review showed it was highly effective and had a good safety profile. Merck announced in 2014 that it would apply for regulatory approval in 2015, but as of early 2016 there was no report of any application. In 2014 Cowen and Co predicted odanacatib will generate a billion USD per year in sales by 2020.
This drug was developed at Merck Frosst in Montreal.
- Le Gall, C. L.; Bonnelye, E.; Clézardin, P. (2008). "Cathepsin K inhibitors as treatment of bone metastasis". Current Opinion in Supportive and Palliative Care 2 (3): 218–22. doi:10.1097/SPC.0b013e32830baea9. PMID 18685424.
- Gauthier JY, Chauret N, Cromlish W, et al. (February 2008). "The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K". Bioorg. Med. Chem. Lett. 18 (3): 923–8. doi:10.1016/j.bmcl.2007.12.047. PMID 18226527.
- "Merck to seek approval of osteoporosis drug, cites safety risks". Reuters. 2014-05-06.
|This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.|